ChemicalBook > CAS DataBase List > 13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID

13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID

CAS No.29623-28-7
Chemical Name:13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID
CBNumber:CB5737950
Molecular Formula:C18H32O3
Formula Weight:296.44
MOL File:29623-28-7.mol

13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID Property

Boiling point 422.7±20.0 °C(Predicted)
Density 0.970±0.06 g/cm3(Predicted)
Flash point 14 °C
storage temp. −20°C
solubility DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS pH 7.2: 1 mg/ml
form Clear to light-yellow liquid.
pka 4.78±0.10(Predicted)
color Colorless to light yellow
FDA UNII 53CYY2A5PM
UNSPSC Code 12352211
NACRES NA.77

Safety

Hazard Codes :F
Risk Statements :11
Safety Statements :7-16
RIDADR :UN 1170 3/PG 2
WGK Germany :3
HazardClass :3

NFPA 704:

	3
0		0

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal wordDanger
Hazard statements H225-H319
Precautionary statements P210-P233-P240-P241-P242-P305+P351+P338

13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID Chemical Properties,Usage,Production

Uses 13(S)-HODE is an inhibitor of tumor cell adhesion in endothelium tissue. 13(S)-HODE is also used to activate GPR132 which may affect autoimmune function and lymph organ size.
Definition ChEBI: An HODE (hydroxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroxy group is at position 13 (with S-configuration).
Biological Activity Expression of 15-lipoxygenase-1 (15-LOX-1) and its main product, 13(S)-HODE, are decreased in human colorectal and esophageal cancers. Certain non-steroidal anti-inflammatory drugs (NSAIDs) can induce apoptosis in human colon cancer cells by increased expression of 15-LOX-1, which down-regulates PPAR-delta through 13-HODE. ', 'PPARγ agonist

in vivo

(S)-Coriolic acid (0-0.6 mg per mouse; Intranasally once a day for 3 consecutive days) causes severe airway dysfunction, airway neutrophilia, mitochondrial dysfunction and epithelial injury^[2].

Animal Model:	BALB/c mice (6-8 weeks)^[2]
Dosage:	0-0.6 mg per mouse
Administration:	Intranasally once a day for 3 consecutive days
Result:	BALB/c mice developed features of mitochondrial dysfunction such as reduction in mitochondrial membrane potential, reduction in complex IV activity in lung mitochondria, and increase in the levels of cytochrome c in lung cytosol.

13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID Preparation Products And Raw materials

Raw materials

Preparation Products

13(S)-HYDROXYOCTADECA-9Z,11E-DIENOIC ACID Suppliers

Global(67)Suppliers